Executive Chairman & CEO

Peter Noymer, PhD

Peter brings to ForCast a depth of experience leading life science startups through the development and commercialization of innovative products.

His focus has been in areas of high unmet medical need across a variety of therapeutic areas, primarily where novel technologies can have a meaningful impact on patient care and outcomes. He holds MS and PhD degrees from MIT and a BS degree from Princeton University.

Co-Founder and CSO, BOD

Jared Foran, MD

Jared is a prominent orthopedic surgeon with over 19 years in practice specializing in total hip and knee replacement. He is a thought leader in the orthopedic community and the inventor or co-inventor of ForCast’s novel delivery technologies. He is Director of Total Joint Replacement at St Anthony Hospital, OrthoColorado Hospital and a Partner at Panorama Orthopedics.

Dr. Foran earned his medical degree from the Johns Hopkins School of Medicine and completed a six-year residency in orthopedic surgery at the University of California San Diego. Following residency, he completed a one year fellowship in total joint arthroplasty at Rush University in Chicago where he trained with world-renowned experts in minimally invasive surgical techniques. complex reconstructions, and treatment of periprosthetic infections.

Chief Innovation Officer & BOD

Charles A. DeCook, MD

Charlie DeCook, a serial entrepreneur and surgeon, leads Total Joint Specialists, an Atlanta-based arthroplasty group revolutionizing outpatient surgery. Having founded and sold seven orthopedic companies, he’s driven innovations in automated impaction, knee sensor technologies, revision tools, navigation platforms, efficiency platforms, and implants.

His current ventures include instrument reprocessing, sterilization methods, 3D planning programs, handheld robotics, knee positioning systems, AI predictive outcome tools, anterior-based hip instrumentation, antimicrobial non-metallic implants, and next-generation smart power tools. Globally recognized for enhancing surgical efficiency, Charlie’s “12 by 12” concept boosts performance and throughput for surgeons.

CFO

Nick Jozwiak, CFA

Nick is a highly regarded financial executive with extensive experience consulting and managing investment deals in startup companies from both sides of the table.  His expertise and rapport with investors have resulted in him serving in a variety of Board of Director positions and formally joining several start-ups in an executive capacity to head finance operations and oversee investor communications, fundraising, and overall strategic direction.  He has raised over $100M in equity and debt financing from a broad array of investors.

He earned the Chartered Financial Analyst (CFA) designation in 2014, and holds a BS degree in Finance, Economics, International Business, and Risk Management & Insurance from The Ohio State University.

BOD

Terry Opgenorth, PhD

Terry has more than 35 years of experience in biopharma; 20 with Abbott’s Pharmaceutical division (now AbbVie) as a bench scientist and executive creating and leading drug discovery teams that advanced 12 drugs into clinical development, including ViekiraPak and Mavyret for HCV, and Novartis’ atrasentan/Vanrafia for IgA nephropathy. He was the internal champion for Abbott-biotech partnerships – Metabolex, Millennium, KaroBio and Enanta.

Since Abbott, Terry has served as the CEO of Vidasym, completing a human proof of concept study of VS-505 in Australia and a successful IND filing in the U.S. for VS-105. He was also co-founder/CSO of VetDC, which developed and launched the first FDA-CVM approved drug for treatment of canine lymphoma (Tanovea) and VP/Exec Director for CSU Ventures’ LAUNCHPAD. Terry is an independent director for VetDC, PhotonPharma and KromaTiD. He holds a B.A. in Liberal Arts (biology) from Calvin University, and M.S. and Ph.D degrees in Physiology from University of Illinois-Urbana.

Pharmaceutical Development

Miguel Guzman, PhD

Miguel has 30 years of experience in pharmaceutical, and biotech development, with expertise in CMC, combination product development, nonclinical development, and regulatory filings. Dr. Guzman was a co-founder of Xoc Pharmaceuticals, where he served as Vice President of Product Development and Technical Operations, responsible for the discovery of NCEs, synthesis and formulation development, nonclinical program, regulatory filings and vendor management.

Prior to Xoc, he served as Director of Technical Operations at MAP Pharmaceuticals, where he was responsible for overseeing and managing CMC activities for the company’s lead product for treatment of migraine. The company was acquired by Allergan in 2013. Prior to MAP, he held multiple technical leadership roles, with increasing levels of responsibility, at 3M Pharmaceuticals and 3M Drug Delivery Systems in product development and marketed product support. Dr. Guzman earned his Ph.D. in Analytical Chemistry from University of Washington and received his B.Sc. in Chemistry from Kentucky Wesleyan College.

Regulatory Affairs

Michele DeVries

Michele entered the bio-pharmaceutical industry after graduating from the University of Minnesota with a Bachelor’s degree in chemical engineering. Over the course of her career, she has focused mainly on early-stage drug development, guiding the industry in a broad range of therapeutic areas including oncology, infectious disease, vaccines, endocrinology, dermatology, psychiatry, neurology, and renal disease.

Her first job was at Tularik (now Amgen) and she held roles of increasing responsibility for companies such as InterMune, VaxGen, Intarcia Therapeutics, VaxGen and finally at Aduro Biotech, culminating as the head of Regulatory, Quality, and Medical Writing. While there she led the company to a Breakthrough Therapy status, obtained Orphan Drug Designation in the US and EU, and oversaw later-stage meetings with various Regulatory Agency bodies, including the Paul Ehrlich Institute, European Medicines Agency, and the US Food and Drug Administration.

In her current consulting capacity, she works with early-phase, small biopharma companies to bring their first-in-human therapies successfully to IND and the clinic. She has obtained Fast Track designation for a WHO Blueprint priority disease, been instrumental in the successful application for Orphan Designation and Qualified Infectious Disease Product, conducted INTERACT, pre-IND, and end-of-Phase 1 meetings with US FDA, and provides guidance on development strategies.

Product Development

Reynaldo Quintana

Reynaldo has over 25 years of product development experience with medical devices and consumer products. Most recently Reynaldo led the full device development of the AcuStream platform at Kedalion Therapeutics which was acquired by Novartis in June of 2022. While at Alexza Pharmaceuticals, Reynaldo led the mechanical design of Alexza’s flagship platform, the STACCATO device, which was approved by the FDA for inhaled systemic drug delivery in 2012. His product development experience in the medical space includes catheters, dental and resuscitation equipment, and inhalation devices. With extensive expertise are system architecture and mechanical design, he brings a focused, lean product development methodology to the team. He earned a BS degree in Mechanical Engineering from the University of Maryland and an MS in Biomedical Engineering from the Catholic University of America.

Commercial Strategy

Larry Yost, R.Ph.

Larry Yost, R.Ph., specializes in supporting the commercial efforts of companies with innovative medical technologies, laboratory diagnostics and genomic bioinformatics tools. He has over 30 years of combined experience with domestic and international medical device, pharmaceutical, and diagnostic companies ranging from large international corporations to small entrepreneurial companies.

Larry has worked with U.S., European and Asia-based companies who have novel medical technologies or diagnostic tests to support market access and commercialization activities. This ranges from technology assessment, KOL development, and the development and implementation of clinical, economic, publication, and reimbursement strategies to tactical implementation of strategic branding and marketing initiatives. Larry has a Bachelor of Science Degree from the Purdue University School of Pharmacy and is a Board-Certified Pharmacist.